TRT and PSA Levels: What a Rise Means and When to Get Checked

TRT and PSA levels are linked: treatment can raise PSA, but a rise alone does not diagnose cancer. A confirmed increase of more than 1.4 ng/mL above baseline in the first year calls for urology review. Your starting PSA, medicines, prostate history, and absolute result can change the next step. ^{1 11}

There's a catch the averages hide. Men who start TRT with very low testosterone can see much bigger jumps, and that changes how your number should be read. We'll show you why the average isn't a safety cutoff. ^{3 4}

What changes the answer for you:

• Your starting PSA. If it was above 4.0 ng/mL before TRT, or above 3.0 ng/mL if you're Black or your father or brother had prostate cancer, the guideline step is a urology check before starting. ¹
• Finasteride or dutasteride. At the prostate-treatment doses discussed below, these drugs can lower PSA by about half over several months. Your clinician needs the dose and start date to read the result. ^{9 10}
• A prostate cancer history. Different rules apply. The 2026 label-change request did not make general TRT screening thresholds suitable for cancer follow-up. ^{6 25}

Published by TRT Provider Guide · Last verified: October 5, 2026 · Editorial research, not medically reviewed · Educational information, not medical advice

Last updated: October 5, 2026.

TRT Provider Guide is the independent decision resource for testosterone replacement therapy — helping U.S. adults understand how low testosterone is evaluated, compare online and local care models and providers, and choose the next step that fits their health needs, fertility plans, budget, state, and care preferences, with every material claim verified and dated.

Who this is for: U.S. adult men using or considering prescribed TRT for testosterone deficiency. Not for interpreting PSA after prostate cancer treatment: use your cancer team's plan. The adult-male study results here are not a monitoring plan for children or for gender-affirming hormone care.

PSA on TRT at a glance

Baseline caveat: for men who started between 2.6 and 4.0 ng/mL, the Endocrine Society says the referral decision should consider both a confirmed rise of more than 1.4 ng/mL and an absolute PSA above 4.0 ng/mL. This is a clinician's decision, not a reason to dismiss a result yourself. ¹

Jump to your situation:

• My PSA just went up on TRT. Don't stop or change your testosterone on your own. Call the person who prescribes it.
• I haven't started TRT yet
• I've had prostate cancer

---

Does TRT raise PSA levels?

Usually, yes, by a small amount: prostate cells make PSA and respond to testosterone. When TRT brings low testosterone back up, PSA often rises a bit, mostly in the first months of treatment. ^{1 3}

First, a quick definition. PSA (prostate-specific antigen) is a protein your prostate makes. A blood test measures it in ng/mL, which means nanograms per milliliter. Don't mix it up with your testosterone result. In the United States, that one is usually reported in ng/dL, a different unit on a different test. ^{1 11}

Here's the key thing about PSA: it's a warning light, not a diagnosis. Normal prostate tissue makes PSA. So does an enlarged prostate. So does an infected prostate. And so does cancer. The National Cancer Institute says there's no single number that cleanly splits a "normal" PSA from an "abnormal" one. ¹¹

So why does TRT nudge it up? Low testosterone can reduce the prostate's PSA output. Bringing testosterone back up can raise that output. It's even written into the drug label. In the 182-day placebo-controlled trial listed on the AndroGel 1.62% prescribing information, a rise in PSA was the most common reported adverse reaction, recorded in about 11% of treated men. That is the label's adverse-reaction count, not the percentage with any small PSA change. ⁸

That's the honest picture. A small rise is common. It also isn't something to ignore. The rest of this page is about telling the two apart.

---

How much does PSA rise on TRT?

There's no single "safe" rise that fits everyone. Three key studies looked at different men and measured the rise in different ways: the older-men trial reported an average one-year rise of about half a point, while a severe-deficiency study reported a larger median change over 6–18 months. Those are different measurements, not a head-to-head comparison. ^{3 4 5}

One number cannot tell you what these studies actually measured. We pulled the three most useful studies and kept each one's real details: who was studied, how long, and what kind of number was reported. Those details are the difference between calm and panic.

What the PSA studies actually measured

Sources: Cunningham et al., J Clin Endocrinol Metab 2019; Sachdev et al., J Endocr Soc 2020; Bhasin et al., JAMA Netw Open 2023. ^{3 4 5}

The extra one-year rise over placebo was about 0.41 ng/mL in the T Trials and 0.15 ng/mL in TRAVERSE. These compare study groups, not your safe allowance. The confidence interval shows the uncertainty around the TRAVERSE group estimate. It is not a range that individual results must stay within. ^{3 5}

Your starting testosterone matters

Look at row two again. Men who started with very low testosterone had a bigger PSA jump. Almost 1 in 3 crossed the 1.4 line at the 6–18-month check. ⁴

One proposed explanation is the saturation model: prostate tissue may respond more to a testosterone increase when the starting level is very low. A retrospective study of 111 men found a statistically significant PSA rise in the subgroup starting at or below 247 ng/dL, but not in the subgroup above it. That study-specific split is not a proven biological cutoff or a rule for reading your PSA. ¹⁸

What it means for you: if your starting testosterone was very low, a bigger early rise may fit the published research. It still has to be checked. Expected and harmless are not the same thing. ⁴

A common mistake to ignore

You may read that PSA rises 1.7 ng/mL on average on TRT. That's wrong. In the T Trials, 1.7 was the rise that only the top 5% of men reached. The average was 0.47. ³

---

What PSA level is too high on TRT?

The Endocrine Society uses review triggers, not one universal "too high" PSA. Before TRT, PSA above 4.0 ng/mL—or above 3.0 ng/mL with higher prostate-cancer risk—needs evaluation before treatment; during TRT, triggers include a confirmed rise of more than 1.4 ng/mL above baseline in the first year, confirmed PSA above 4.0 ng/mL, or an abnormal prostate exam. Starting PSA and urinary symptoms also affect the decision. ¹

Two words in that answer do a lot of work.

"Confirmed" means a repeat test confirmed the elevation, not necessarily the exact same number. PSA bounces around, so one high result isn't the final word. ^{1 11}

"First year" matters because the 1.4 rule is built for the first 12 months of TRT. After that, the Endocrine Society says to follow prostate-screening guidance for your age and race. That does not mean ignoring a new rise or new symptoms. ¹

And remember: a referral line is not a cancer diagnosis. It means "a specialist should look at this." Crossing a line does not mean a biopsy or cancer treatment is automatic. ¹¹

The guideline lines, side by side

Here's what the source texts say about PSA and testosterone. The U.S. TRT guideline, European TRT guideline, and general prostate-screening recommendations answer different questions.

The baseline caveat: if PSA before TRT was 2.6–4.0 ng/mL, the Endocrine Society says to consider both a confirmed rise of more than 1.4 ng/mL above baseline and an absolute PSA above 4.0 ng/mL when deciding on referral. Treatment-related change and test variability can otherwise lead to unnecessary referral. A symptom or abnormal exam still needs assessment. ¹

The AUA/SUO issued a screening-guideline amendment in 2026 covering newer evidence on imaging, biomarkers, and biopsy decisions. The screening ages and intervals shown here are from the published 2023 text, not a new TRT-specific schedule. ^{16 17}

Who counts as "higher risk"? The Endocrine Society names Black men and men with a first-degree relative, such as a father or brother, with prostate cancer. AUA/SUO screening guidance also addresses strong family history and inherited gene changes linked to risk. These are reasons to discuss an earlier or different screening plan, not proof that cancer is present. ^{1 16}

Seeing "0.4 per year" or "0.6 baseline" online? Do not use either as a current, stand-alone rule for referral or biopsy. The Endocrine Society updated its 2010 testosterone guideline in 2018. AUA/SUO screening guidance says how fast PSA rises should not be the only reason for additional tests or a biopsy. ^{1 16}

Haven't started TRT yet?

Your baseline PSA, your age, and your family history help decide whether your first stop should be a urologist, your primary care doctor, or an online program. A high result needing evaluation comes before shopping for a new TRT clinic. ¹

The right TRT provider is not the same for every person — it depends on whether low testosterone has been properly evaluated, your symptoms and health history, your fertility plans, your state, your insurance or cash-pay preference, your treatment-format preference, your budget, and whether online or in-person care is the better starting point. Some situations belong with primary care, urology, endocrinology, reproductive urology, or urgent or emergency care when the symptoms warrant it. Because a general answer cannot resolve those for you, use TRT Provider Guide's Find My TRT Path tool to map your situation to the right care route and the questions to ask before you pay.

Want to know where your first stop should be? Map my care route with Find My TRT Path → Free and educational. It can't read a PSA result or replace your clinician.

---

What to do if your PSA went up on TRT

Don't panic, and don't stop or change your testosterone on your own; call the clinician who prescribes it. A repeat test often helps confirm a newly high result, and your clinician decides when it should happen and whether you need urology review. An exam, additional blood tests, or an MRI may help decide about biopsy, but not everyone needs the same sequence. ^{1 11 16}

The patient portal flags a number in red, and your mind goes straight to the worst case. Will they take me off TRT? Does this mean cancer? Is the number going to keep climbing? Those are questions to bring to the clinician, not conclusions the red flag can answer.

Here's what usually happens, step by step.

1. Call your prescriber. Ask who owns this result: them, the doctor who ordered the test, or a urologist.
2. Check the test conditions. Ejaculation, vigorous cycling, a urinary infection, or a recent prostate procedure can affect PSA. Tell the clinician what happened rather than assuming it explains the result. (Full list below.) ^{11 13}
3. Get a repeat test if your clinician agrees. The National Cancer Institute describes a repeat in 6–8 weeks for an abnormal screening result in someone without symptoms. That is not a waiting rule for every result on TRT or for someone with urgent symptoms. ¹¹
4. Compare to your pre-TRT baseline, not just your last result. The first-year guideline trigger measures change from before treatment started. ¹
5. Ask whether urology review is needed. A urologist may do a prostate exam, order a more detailed PSA test (such as percent-free PSA), or order an MRI. A biopsy is not automatic, and neither is an MRI before every biopsy. ^{11 13}
6. Ask what to do about TRT while you wait. Your prescriber should give you a treatment plan while the result is checked, rather than leaving you to decide from a lab flag. ^{1 8}

Symptoms that shouldn't wait for another test

Get medical care right away if you can't urinate or you have severe belly pain. That can be urinary retention, a medical emergency. Fever or chills with painful urination or pelvic pain also needs prompt medical care. ^{14 24}

"My PSA dropped after I stopped TRT. Am I in the clear?"

A lower number is not proof there's no cancer. PSA can fall after testosterone treatment ends, but the change alone cannot establish why it was high. If you crossed a guideline line, finish the evaluation your clinician started. ^{3 11}

Should you switch clinics because yours wants a urology check?

No. A clinic asking for urology follow-up is doing its job. That's the clinic you want. Ask what finding triggered the request, what records are needed, and who will coordinate the next step. Switching to find someone who will skip the check doesn't make the number go away.

Got two PSA numbers and an appointment coming up? Fill in the free PSA Appointment Brief → Set aside a few minutes. Print it or copy it into a message to your clinician.

---

What else can change a PSA result?

PSA moves for many reasons besides cancer and TRT: ejaculation, vigorous cycling, a urinary or prostate infection, and some procedures can raise it for a while. Finasteride and dutasteride can lower it, so the dose and treatment duration matter when your clinician reads the result. ^{9 10 11 13}

Things that can push PSA up or down

Sources: National Cancer Institute; American Cancer Society. ^{11 13}

Do not start, stop, or change a medicine or supplement to alter the test. Tell your clinician what you take. ¹²

Even the prep advice doesn't agree

How long should you wait after ejaculating before a PSA test? MedlinePlus says 24 hours. The National Cancer Institute says to avoid activities such as ejaculation and vigorous cycling that can raise PSA for 2 days. ^{11 12}

Our take: ask the clinician who ordered the test which preparation instructions to follow. Consistent preparation helps comparison, but it does not make 24 and 48 hours equivalent or rule out every cause of a high result. Tell the clinician if you could not follow the instructions. ^{11 12 15}

Taking finasteride or dutasteride? Read this

These drugs are 5-alpha reductase inhibitors. Finasteride is used at different doses for hair loss or an enlarged prostate; dutasteride's U.S. label is for an enlarged prostate. At the doses below, both lower PSA by about half over several months, so your lab's "normal" flag may not tell the whole story. Here's what the prescribing information tells doctors: ^{9 10 13}

Two cautions. These label rules are written for the prostate doses shown above. If you take a lower hair-loss dose, tell your clinician the dose and the date you started, and let them make the adjustment. And don't start or stop either drug to change a PSA number.

Enlarged prostate (BPH) and PSA

BPH means benign prostatic hyperplasia: noncancerous enlargement of the prostate. An enlarged prostate can raise PSA even without cancer. That's one reason two men with the same number can need different next steps. Tell your clinician about a weak stream, trouble starting, or worsening urinary symptoms; do not use BPH as a reason to dismiss a rise. ^{1 13}

---

Do you need a PSA test before TRT, and how often after?

The Endocrine Society recommends a shared discussion about prostate monitoring for men 55–69 with more than 10 years' life expectancy, and for higher-risk men 40–69. For men who choose monitoring, its plan includes PSA and a prostate exam before treatment and again 3–12 months after starting, then age- and risk-based screening. A baseline PSA helps assess risk; it cannot rule out cancer by itself. ^{1 11}

Your baseline gives later results context

Without a pre-TRT number, you cannot calculate how much PSA changed from before treatment. A result of 3.8 ng/mL still gives your clinician information, but not whether it rose 0.3 points or 3 points after TRT. ^{1 11}

Already on TRT without a baseline? Ask your prescriber whether an older result exists in your medical records and how to set a follow-up plan now. A missing baseline does not mean a high result should be ignored. ^{1 11}

Before your baseline test:

• Ask whether to avoid ejaculation and hard cycling first, and for how long
• Ask whether the blood draw should happen before a prostate exam that day
• Tell them about finasteride, dutasteride, and any supplements
• Mention any recent urinary infection or prostate procedure
• Get a copy of the report with the date, the units, and the lab name

Preparation and medicine questions: ^{11 12 13}

A PSA timeline on TRT

A clinician may set a different interval because of your risk or earlier results. More frequent screening is not automatically better: it can lead to false alarms and unnecessary tests. The thing that matters is that someone reads the result and acts on it. Agree on who will do that and when you should hear back. ^{11 16}

For the full lab schedule (testosterone, hematocrit, and the rest), see How often should you get bloodwork on TRT? For the full starting panel, see What blood tests are required before TRT?

---

Does TRT cause prostate cancer?

TRAVERSE did not find a statistically significant increase in prostate cancer among the screened men studied, but it did not establish equal risk. High-grade cancer was found in 0.19% of men on testosterone and 0.12% on placebo over an average follow-up of 33 months. Few cancer events and limited follow-up leave long-term safety unresolved. ⁵

TRAVERSE provides a large randomized comparison of testosterone gel and placebo. Here's what it found on the prostate: ⁵

Source: TRAVERSE prostate-safety report. ⁵

The European Academy of Andrology's guideline likewise describes a lack of a documented short-term increase in prostate cancer, while stressing the lack of long-term safety data. That is not a promise of zero risk. ¹⁵

What TRAVERSE can't tell you

The good news comes with fine print, and it matters:

• The men were screened first. Anyone with a PSA above 3.0 ng/mL, a prostate lump, severe urinary symptoms, or past prostate cancer was left out. The PSA exclusion was above 1.5 ng/mL for men taking a 5-alpha reductase inhibitor.
• About three years isn't a lifetime. Prostate cancer often grows slowly.
• The testosterone group used a gel. Results may not carry over exactly to injections or other forms. ⁵

So the fair reading is this: in carefully checked men, this trial did not find a clear increase in prostate cancer during its follow-up. It does not mean every PSA rise is harmless. That's exactly why the follow-up rules still exist. ^{1 5}

---

What changed for TRT and the prostate in 2026?

In June 2026, the FDA requested narrower prostate-cancer label language while retaining recommendations to assess prostate-cancer risk before and during treatment. A request is not proof that every product's label has already changed. The Endocrine Society then said long-term prostate safety is still not established. ^{2 6}

Here's the timeline, and the difference between a request and a revised label:

The takeaway is simple. The requested wording is less restrictive about prostate cancer, but the announcement did not drop follow-up. If anyone tells you it means you can skip prostate monitoring, that's not what the FDA said. ⁶

---

Can you start TRT with a high PSA or after prostate cancer?

An unexplained high PSA needs evaluation before a TRT decision; it is not an automatic "never." Prostate cancer survivors face a different, specialist-led decision. The FDA's 2026 request would narrow the prostate-cancer contraindication to metastatic cancer, but long-term prostate safety is still not established. ^{1 2 6}

A high PSA before treatment

If your baseline is above 4.0 ng/mL (or above 3.0 ng/mL and you're higher risk), the Endocrine Society says to get it checked before starting. That usually means a repeat test and a urology visit. Sometimes it also means an MRI or more detailed PSA tests. Whether treatment is appropriate depends on what that evaluation finds. The point is to know what you're working with first. ^{1 11}

After prostate cancer

This is not a general-TRT-page decision. Here's where things stand:

• The 2018 Endocrine Society guideline recommends against TRT in men with prostate cancer. ¹
• The European Academy of Andrology describes scarce safety evidence after treated prostate cancer and calls for an individual discussion with the treating urologist or oncologist in carefully selected cases. ¹⁵
• The FDA's June 2026 request would narrow the prostate-cancer contraindication to metastatic cancer. It does not by itself establish that TRT is suitable for a particular survivor or update every product label. ^{6 8}

One more thing: the general screening cutoffs on this page are not cancer-recurrence cutoffs. After surgery or radiation, PSA is used to watch for cancer coming back, and that follows a different set of rules. Talk with the urologist or oncologist who treated you. ²⁵

Observational studies have also looked at TRT in men on active surveillance, which means monitoring a known cancer rather than treating it right away. These findings need further confirmation and are for your specialist to weigh, not a basis for self-starting treatment. ²⁶

---

Can an online TRT clinic monitor your PSA properly?

An online program can arrange PSA blood testing, but testing alone is not a complete follow-up plan. A video visit cannot include a hands-on prostate exam; the program would need to arrange or coordinate local care when one is needed. An unexplained high PSA or concerning symptoms need clinical evaluation, while family history alone is a reason to discuss risk—not an automatic requirement to see a urologist first. ^{1 13 24}

Ask these 5 questions before you pay any TRT provider

1. Is PSA in my first blood test?
2. When is PSA rechecked after I start?
3. Who reads the result, and how fast?
4. What number makes you refer me to a urologist?
5. Will you send my results to my own doctor?

A provider that can't answer all five clearly has not given you enough information to pay with confidence. Ask whether repeat PSA tests, extra blood draws, local exams, and urology visits cost extra; a membership price does not answer those questions.

How the programs we track handle PSA

TRT Provider Guide has affiliate relationships with some providers discussed here. This page does not link to paid enrollment; the provider sources below are ordinary reference links. See our affiliate disclosure.

Last verified: October 5, 2026. These are provider-stated facts from each company's own pages, not results of testing a program ourselves.

A missing public detail is not proof a provider omits that service. Ask each program the five questions above before you sign up. These disclosures do not establish that one program offers better prostate care than another.

What we actually verified (October 5, 2026)

Checked: Male Excel's TRT and HRT-cost pages; Taurus Meds' homepage and the readable public portion of its intake landing page; Hone Health's PSA page.

Provider-stated, not independently tested: Male Excel lists PSA in its initial at-home kit, 60-day reviews, and comprehensive blood testing every 6 months. It advertises $99 for the initial kit and consultation and $99/month for membership; medication and shipping are separate, and it does not accept insurance. Hone lists PSA in its men's hormone panel. Male Excel also says HSA/FSA reimbursement may be available; check your plan rather than assuming reimbursement. ^{20 21 23}

Not confirmed from those pages: PSA in every scheduled repeat panel; repeat morning testosterone tests included in the initial fee; Taurus Meds' PSA markers or repeat schedule; the exact Hone initial package that includes PSA; when Male Excel's monthly billing starts; local referral arrangements; each patient's full cost, exact medication, FDA-approval status, or dispensing pharmacy.

Limits: We did not buy a kit, complete clinical intake, test a membership, contact support, or independently check individual clinician or pharmacy licenses for this page. Public disclosure is not proof of clinical quality or availability in your state.

Our process: How We Review TRT Providers.

---

Is Male Excel a good fit if PSA is on your mind?

PSA in the first kit is useful, but it is not enough to call a program the right fit for your prostate care. Male Excel lists PSA in its initial at-home test and comprehensive blood testing every 6 months, but its public page does not confirm PSA in every repeat panel or local exam arrangements. An unexplained high result belongs with your prescriber or a urologist before a new enrollment. ^{1 20}

An online visit cannot include an in-person prostate exam. That limitation matters when an exam is needed. Male Excel's at-home starting kit is a convenience, not a substitute for examining or investigating a concerning finding; its public lab schedule does not establish that every follow-up test happens at home. ^{20 24}

Who may find its testing process useful: adults comparing at-home starting panels that include PSA, after discussing whether that testing and care setting fit their needs. A "normal" PSA—or not having a PSA yet—is not proof that someone is eligible for TRT.

Who should look elsewhere:

• An unexplained PSA above 4.0 ng/mL, or above 3.0 ng/mL if you're higher risk → evaluation before starting (Urologist vs. endocrinologist for low T). For a rise during TRT, use the baseline and confirmation rules above. ¹
• Any prostate cancer history → your urologist or oncologist ^{1 15}
• Trying to conceive soon → testosterone can lower sperm production; start with a fertility-aware clinician, often a reproductive urologist. See Best TRT providers for fertility. ^{1 15}

Two things to know before you start:

1. How your diagnosis gets confirmed. Male Excel describes using lab results and symptoms. The Endocrine Society requires compatible symptoms or signs plus consistently low testosterone, confirmed with repeat early-morning fasting testing using an accurate assay; one cutoff or a symptom assessment is not a diagnosis. Ask how two separate morning tests are obtained and whether a repeat costs extra. ^{1 2 20}
2. The real cost. Male Excel doesn't take insurance, and medication costs extra. Twelve $99 membership charges total $1,188. Adding the advertised $99 initial kit and consultation gives $1,287 before medication, shipping, or any separate outside care. This assumes 12 membership charges plus the initial fee; the billing start date and your complete first-year quote need confirmation. See the full breakdown on our Male Excel cost page. ^{20 21}

Still comparing the program after those limits? Review Male Excel's costs and lab questions → This is a cost guide, not clinical clearance. For a PSA result that has changed, contact the clinician responsible for it first.

Before paying any program, also ask for the exact testosterone product and dispensing pharmacy. FDA-approved testosterone products and compounded testosterone preparations are different categories. Compounded drugs are not FDA-approved. We did not verify which exact product a reader would receive from these programs. ²⁷

Want to compare how other programs handle labs? See TRT providers with ongoing monitoring and Best online TRT providers for men over 50.

---

How can you use your PSA Appointment Brief?

Bring your current and earlier PSA reports, a list of your medicines, the date you started TRT, and your prostate history. This worksheet keeps them together for your clinician and helps you record the follow-up plan. It does not interpret your result or guarantee a decision in one visit.

Print this page section, or copy it into a note. Keep the completed version in your own records and share it with your clinician, not in a public comment or a provider-comparison tool.

A. The question I need answered

"My PSA result has changed. What needs to be checked, who will review it, and what should I do about my prescribed treatment while we follow up?"

B. Records to bring

C. My PSA results — copy them exactly as the report shows

D. Questions to ask

1. Which earlier result should we compare this one with?
2. Does this need a repeat test, and when?
3. Could my medicines, a recent infection, activity, or a procedure have affected it?
4. Does my starting PSA, my starting testosterone, or how long I've been on TRT change what this means?
5. Should a urologist review this? Who will set that up?
6. What should I do about my TRT while this is being checked?
7. Who will contact me with the next result, and when should I call if I haven't heard back?

E. Message you can send your clinician

Hello [clinician or team name]. My PSA result from [date] was [result], compared with [earlier result] on [earlier date]. I started TRT on [date]. My current medicines are [list, including finasteride or dutasteride and start dates]. Does this result need a repeat test or a urology review? Please let me know how to prepare for any repeat test, and what you recommend for my treatment while we follow up. Who will coordinate the next step?

F. The plan we agreed on

• Next test or appointment:
• Who's responsible:
• Instructions I was given:
• When I should hear back:
• Office contact:

If you can't urinate or have severe belly pain, get medical care now. Don't wait to fill this out.

---

How did we research this guide?

This guide draws on clinical guidelines, original trial reports, U.S. government health information, FDA and HHS announcements, and drug labels we checked on a set date. The tables pull these together in one place. We didn't test any treatment, review anyone's personal results, or have a clinician review this page.

What we did, on October 5, 2026:

• Read the Endocrine Society's 2018 testosterone guideline and its July 2026 statement
• Read the EAA's 2020 guideline, the published AUA/SUO 2023 prostate-screening text, and the abstract of its 2026 amendment
• Pulled PSA results straight from the original T Trials, severe-hypogonadism, and TRAVERSE papers, keeping each study's own population and type of number
• Checked the June 2026 HHS/FDA labeling announcement, the AndroGel 1.62%, Proscar, and Avodart labels, and the NCI, MedlinePlus, and American Cancer Society PSA pages
• Checked the public provider disclosures listed in the verification box; we did not verify clinical performance, every test package, or private account and checkout terms

What this guide can't do: interpret your result, tell you whether to start or stop TRT, or predict your personal risk. Your clinician does that, with your full history.

Spot something out of date? Our corrections page explains how we fix it. Our wider standards are on our editorial standards page. Our privacy policy explains how the site handles information.

---

What else should you know about TRT and PSA levels?

A PSA result needs context: your baseline, repeat result, medicines, symptoms, and prostate history. These answers explain the main follow-up questions without turning one number into a diagnosis or treatment instruction. ^{1 11}

Does TRT increase PSA levels?

Usually a little, mostly in the first year. In the T Trials, PSA rose about 0.47 ng/mL in a year on testosterone, compared with 0.06 on placebo. ³

What is a normal PSA on TRT?

There's no single normal number. What matters is your change from your pre-TRT baseline, whether a repeat test confirms it, your absolute result, medicines, symptoms, and prostate history. ^{1 11}

How much PSA increase is too much on TRT?

The Endocrine Society's review triggers include a confirmed rise of more than 1.4 ng/mL above baseline in the first 12 months, confirmed PSA above 4.0 ng/mL, or an abnormal prostate exam. For a starting PSA of 2.6–4.0 ng/mL, its referral advice considers both the confirmed rise and the absolute result. These are review triggers, not a cancer diagnosis. ¹

Can a PSA below 4 still need follow-up?

Yes. A confirmed change, finasteride or dutasteride use, your family history, or a prostate exam finding can matter even below 4. A number under the lab cutoff isn't automatic clearance, and PSA speed alone should not decide whether you need a biopsy. ^{1 9 10 16}

Can I start TRT with a PSA of 4?

A result of exactly 4.0 ng/mL does not, by itself, clear or rule out TRT. The Endocrine Society flags results above 4.0 ng/mL, or above 3.0 ng/mL with higher risk, for evaluation before treatment. A clinician still needs to assess a result at or below those numbers in context. ^{1 11}

Should I stop TRT if my PSA goes up?

Don't stop or change it on your own. Call your prescriber. A repeat test often helps confirm the result, and your clinician decides what happens to treatment meanwhile. ^{1 8}

Does every PSA rise mean a biopsy?

No. A clinician may repeat the test, do an exam, order more detailed PSA tests, or order an MRI. Not everyone needs every test before a biopsy decision, and a biopsy is not automatic. ^{11 13}

Does TRT cause prostate cancer?

TRAVERSE did not find a statistically significant difference in prostate cancer among the screened men studied. That does not prove equal risk, and long-term safety is still not established. ⁵

Did the 2026 FDA changes end PSA monitoring?

No. The June 2026 request kept risk assessment before treatment and monitoring during it. And a request isn't the same as a changed label on every product. ^{6 8}

How often should PSA be checked on TRT?

For men who choose the Endocrine Society monitoring plan: before starting, 3–12 months after, then screening based on age and risk. An abnormal result or new symptoms may need a different schedule. ¹

Does finasteride affect PSA on TRT?

Yes. Finasteride 5 mg and dutasteride 0.5 mg lower PSA by about half over several months. Hair-loss dosing should not automatically be given the same adjustment. Tell your clinician the drug, the dose, and when you started, so they can adjust how they read your result. ^{9 10 13}

Do injections raise PSA more than gel?

A 2020 pooled analysis found a small PSA increase in the injection subgroup compared with placebo. That does not establish that injections raise PSA more than gel in a direct comparison, or that switching formats would solve a high result. Ask your prescriber about the result rather than switching treatment yourself. ¹⁹

Does PSA go down if you stop TRT?

It can. PSA can fall after treatment ends, but a drop does not prove testosterone was the only cause or that there's no cancer. If you crossed a guideline line, finish the evaluation. ^{3 11}

Can I use these numbers after prostate cancer treatment?

No. After surgery or radiation, PSA is used to watch for cancer coming back, and that follows different rules. Use the plan from the team that treated you. ²⁵

Can an online TRT clinic check PSA?

Programs can arrange blood testing, but a hands-on prostate exam requires an in-person visit. Ask whether PSA is in your initial and repeat panels, who reviews the result, and how local exams and referrals are handled. ^{20 23 24}

---

Still not sure which TRT care route fits you? Use our free Find My TRT Path tool.

Educational information, not medical advice. Your clinician must interpret your PSA result. Testosterone is a Schedule III controlled substance in the United States and requires a valid prescription. If you can't urinate or have severe belly pain, seek urgent or emergency care. ^{8 14}

---

Sources

Clinical and provider sources below were checked on October 5, 2026. Guideline publication dates and the product-label revisions checked are shown separately.

1. Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. Recommendations 2.2–2.3 and 3.2; Table 9 and its technical remarks.

2. Endocrine Society. Statement on Testosterone Replacement Therapy. July 16, 2026.

3. Cunningham GR, et al. Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial. J Clin Endocrinol Metab. 2019;104(12):6238–6246. Abstract and Tables 2–3.

4. Sachdev S, Cucchiara AJ, Snyder PJ. Prostate-Specific Antigen Concentrations in Response to Testosterone Treatment of Severely Hypogonadal Men. J Endocr Soc. 2020;4(11):bvaa141. Results and Tables 2–3.

5. Bhasin S, et al. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Netw Open. 2023;6(12):e2348692. Results, PSA analysis, and limitations.

6. U.S. Department of Health and Human Services. HHS Announces Requested Updates to Testosterone Therapy Product Labels. June 18, 2026.

7. U.S. Food and Drug Administration. FDA Issues Class-Wide Labeling Changes for Testosterone Products. February 28, 2025.

8. DailyMed. AndroGel 1.62% (testosterone gel) prescribing information. The entry checked was revised October 2025. Sections 4, 5.1, 6.1, and 9.1.

9. U.S. Food and Drug Administration. Proscar (finasteride 5 mg) prescribing information. 2026 label; section 5.1.

10. DailyMed. Avodart (dutasteride 0.5 mg) prescribing information. Revised October 2023; section 5.1.

11. National Cancer Institute. Prostate-Specific Antigen (PSA) Test. Updated January 31, 2025.

12. MedlinePlus. Prostate-Specific Antigen (PSA) Test. Test preparation and interpretation.

13. American Cancer Society. Screening Tests for Prostate Cancer. Factors that can affect PSA and follow-up testing.

14. National Institute of Diabetes and Digestive and Kidney Diseases. Symptoms & Causes of Urinary Retention.

15. Corona G, et al. European Academy of Andrology (EAA) Guidelines on Investigation, Treatment and Monitoring of Functional Hypogonadism in Males. Andrology. 2020;8(5):970–987. Endorsed by the European Society of Endocrinology; recommendations 19–23 and 28–32.

16. Wei JT, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. J Urol. 2023;210(1):46–53. Published guideline text.

17. Lin DW, et al. Updates to Early Detection of Prostate Cancer: AUA/SUO Guideline (2026). J Urol. 2026;215(5):491–501. Published amendment abstract.

18. Sakonponwasin N, et al. The Prostate Saturation Point after Testosterone Replacement Therapy in Testosterone Deficiency Patient. J Med Assoc Thai. 2021;104:1465–1470. Published study abstract reproduced in the author-publications record; this is an exploratory retrospective study, not a clinical threshold guideline.

19. Kim DK, et al. Association Between Prostate-Specific Antigen and Serum Testosterone: A Systematic Review and Meta-Analysis. Andrology. 2020;8(5):1194–1213. Institutional research record and abstract.

20. Male Excel. TRT Online. Public, provider-stated initial panel, membership, pricing, and follow-up details; checked October 5, 2026.

21. Male Excel. HRT Costs. Public, provider-stated membership, medication, and shipping disclosures; checked October 5, 2026.

22. Taurus Meds. Homepage. Public testing information; checked October 5, 2026.

23. Hone Health. Prostate-Specific Antigen (PSA). Public statement that PSA is included in its men’s hormone panel; checked October 5, 2026.

24. National Institute of Diabetes and Digestive and Kidney Diseases. Prostatitis: Inflammation of the Prostate. Symptoms requiring prompt medical care.

25. American Cancer Society. Following PSA Levels During and After Prostate Cancer Treatment.

26. Kaplan-Marans E, Zhang TR, Hu JC. Oncologic Outcomes of Testosterone Therapy for Men on Active Surveillance for Prostate Cancer: A Population-based Analysis. Eur Urol Open Sci. 2024;60:36–43. Retrospective study; published abstract.

27. U.S. Food and Drug Administration. Understanding the Risks of Compounded Drugs.